SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
RCUS

Arcus Biosciences, Inc. (RCUS)

NYSE: RCUS · USD
Healthcare · Biotechnology
$15.62-$0.16 (-1.01%)
 
Market cap
$2.25B
Insider Score
Analyst consensus
Market Cap$2.25B-26.4%
Revenue (ttm)$100.00M
Net Income-$453.00M
EPS-$3.60
Shares Out143.99M
PE Ration/a
Forward PE-5.05
Dividendn/a
Ex-Dividend Daten/a
Volume1,671,434
Open$15.66
Previous Close$15.78
Day's Range$15.56 - $16.66
52-Week Range$15.56 - $31.73
Beta1.09
AnalystsStrong Buy
Price Target$40.92(+161.95%)
Earnings DateNov 4, 2026

About RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Address
3928 Point Eden Way, Hayward, CA, 94545, United States
Market Cap
2.25 billion
Employees
601
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$3.89M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
4 Buy0 Hold0 SellAvg target $42.67 (+173.2%)

4 firms rating RCUS in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-1.01%
5 Days
-10.38%
1 Month
-19.32%
6 Months
-33.33%
1 Year
-26.42%

$RCUS stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in RCUS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by RCUS's directors and management

Net Shares Purchased by Insiders−80k−40k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

RCUS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

RCUS Revenue by Segment

$10.00MTotal
License and development services$8.00M80.00%
R&D services$1.00M10.00%
Other$1.00M10.00%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New RCUS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to RCUS from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from RCUS’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
45

News check: BofA price target cut and fund dumping outweigh conference participation; mixed signals on stock momentum and analyst positioning.

Recent Insider Activity

Buys
0
Sells
12
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

CNCRLoncar Cancer Immunotherapy ETF3.32%
IDNAiShares Genomics Immunology and Healthcare ETF1.38%
PSCHInvesco S&P SmallCap Health Care ETF1.04%
CANCTema Oncology ETF0.76%
XSMOInvesco S&P SmallCap Momentum ETF0.59%
BBCVirtus Biotech Clinical Trials ETF0.58%
TDNAT. Rowe Price Biotech ETF0.42%
XBIState Street SPDR S&P Biotech ETF0.37%
DWASInvesco Dorsey Wright SmallCap Momentum ETF0.28%
VIOGVanguard S&P Small-Cap 600 Growth ETF0.18%
IJTiShares S&P Small-Cap 600 Growth ETF0.15%
SLYGState Street SPDR S&P 600 Small Cap Growth ETF0.15%

Weight is the stock’s share of each fund’s holdings.